Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Rating Increased to Strong-Buy at Jefferies Financial Group

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was upgraded by Jefferies Financial Group from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

SGIOY has been the topic of a number of other research reports. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

OTCMKTS SGIOY opened at $8.70 on Tuesday. Shionogi & Co., Ltd. Unsponsored ADR has a 1 year low of $7.65 and a 1 year high of $12.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46. The stock has a market capitalization of $14.81 billion, a PE ratio of 10.88, a P/E/G ratio of 3.47 and a beta of 0.09. The company’s 50 day simple moving average is $8.99 and its two-hundred day simple moving average is $9.90.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.15 by $0.03. The firm had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%. Analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.